WILMINGTON, Del. / Aug 16, 2023 / Business Wire / Phreesia, a leader in patient intake, outreach and activation, is pleased to announce it has been selected by The Software Report as one of the “Top 100 Software Companies of 2023.” The annual program evaluates companies based on a range of factors, including product functionality, innovative capabilities, environmental, social and governance (ESG) involvement, and long-term viability, among others. This is the second year in a row that Phreesia made the list. Other awardees this year include Adobe, Groove and Pantheon.
“It’s an honor to be recognized as part of this impressive list of software companies,” said Phreesia CEO Chaim Indig. “We feel strongly that our investments in our products and people are furthering our mission to activate patients in their care and drive better health outcomes, and we’re extremely proud to be known as a SaaS innovator in the healthcare space.”
In its announcement, The Software Report called awardees “companies to watch,” noting that “irrespective of the company's size or age, this year’s awardees are making a significant impact on the software industry within their specific domains, all while providing exceptional value to their customers.”
For more information on Phreesia, visit www.phreesia.com.
About Phreesia
Phreesia is the trusted leader in patient activation, giving providers, health plans, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 120 million patient visits in 2022–more than 1 in 10 visits across the U.S.–scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.
Last Trade: | US$25.16 |
Daily Change: | 1.32 5.54 |
Daily Volume: | 704,277 |
Market Cap: | US$1.460B |
December 09, 2024 October 28, 2024 October 01, 2024 September 04, 2024 July 30, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB